Skip to main content
SpringerLink
Log in

Noninflammatory Vascular Diseases of the Kidney

  • Chapter
Therapy of Renal Diseases and Related Disorders

  • 173 Accesses

Abstract

The kidneys are highly vascularized organs that normally receive 20–25% of the cardiac output. The arterial network of the kidney is highly specialized and is adapted to the regulatory functions of this organ. It is not unusual, therefore, to encounter functional and structural changes in the kidneys in diseases of the vasculature of any etiology. The compromise in renal function that ensues, in turn, adversely affects the course of the primary vascular disease. Conversely, the successful therapy of either the underlying vascular disease or the consequent deterioration of renal function will favorably alter the course of the other. This chapter deals only with the noninflammatory vascular diseases that compromise renal blood flow and alter renal function. The specific entities to be covered are: essential hypertension, malignant hypertension, renovascular hypertension, scleroderma, embolic diseases, and renal vein thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Veterans Administration Cooperative Study on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. I. Results in patients with diastolic blood pressure averaging 115 through 129mmHg. J A M A 202:1028–1034, 1967.

    Article  Google Scholar 

  2. Veterans Administration Cooperative Study on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90–114mmHg. J A M A 213:1143–1152, 1970.

    Article  Google Scholar 

  3. Hypertension Detection and Follow-Up Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. J A M A 242:2652–2671, 1979.

    Google Scholar 

  4. Kaplan NM: The role of the kidney in hypertension. Hypertension 1: 456–461, 1979.

    PubMed  CAS  Google Scholar 

  5. Ferris TF: The kidney and hypertension. Arch Intern Med 142:1889–1895, 1982.

    Article  PubMed  CAS  Google Scholar 

  6. Suki WN: The kidney in hypertension. Contr Nephrol 7:290–308, 1977.

    CAS  Google Scholar 

  7. Berglund G, Andersson O, Wilhelmsen L: Prevalence of primary and secondary hypertension: Studies in a random population sample. Br Med J 2:554–558, 1976.

    Article  PubMed  CAS  Google Scholar 

  8. Moyer JH, Heider C, Pevey K, Ford RV: The vascular status of a heterogeneous group of patients with hypertension, with particular emphasis on renal function. Am J Med 24:164–176, 1958.

    Article  PubMed  CAS  Google Scholar 

  9. Rostand, SG, Kirk KA, Rutsky EA, Pate BA: Racial differences in the indicence of treatment for end-stage renal disease. N Engl J Med 306:1276–1279, 1982.

    Article  PubMed  CAS  Google Scholar 

  10. Russell RP, Whelton PK: Hypertension in chronic renal failure. Clinical presentation, prognosis, pathophysiology and treatment. Am J Nephrol 3:185–192, 1983.

    Article  Google Scholar 

  11. Sullivan JM, Johnson JG: The management of hypertension in patients with renal insufficiency. Sem Nephrol 3:40–51, 1983.

    Google Scholar 

  12. Lifschitz MD: Hypertension in chronic renal failure. Con-temp Issues Nephrol 4:222–246, 1981.

    Google Scholar 

  13. Vertes V, Cangano JL, Berman LB, Gould A: Hypertension in end-stage renal disease. N Engl J Med 280:978–980, 1969.

    Article  CAS  Google Scholar 

  14. Weidmann P, Maxwell MH, Lupu AN, Lewin AJ, Massry SG: Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med 285:757–762, 1971.

    Article  PubMed  CAS  Google Scholar 

  15. Zuccheli P, Santoro A, Zuccala A: Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 8:163–168, 1988.

    Google Scholar 

  16. Davies DL, Schalekampp MA, Beevers DG, Brown JJ, Briggs JD, Lever AF, Medina AM, Morton JJ, Robertson JIS, Tree M: Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure. Lancet 1:683–687, 1973.

    Article  PubMed  CAS  Google Scholar 

  17. Warren DJ, Ferris TF: Renin secretion in renal hypertension. Lancet 1:149–163, 1970.

    Google Scholar 

  18. Weidmann P, Beretta-Piccoli C, Steffen F, Blumberg A, Reubi F: Hypertension in terminal renal failure. Kidney Int 9:294–301, 1976.

    Article  PubMed  CAS  Google Scholar 

  19. Campese VM, Romoff MS, Levitan D: Autonomic nervous system dysfunction in uremia. Kidney Int 19:246–253, 1981.

    Article  Google Scholar 

  20. Morgenson CE: Progression of nephropathy in long-term diabetes with proteinuria and effect of initial antihyperten-sion treatment. Scand J Clin Lab 36:384–388, 1976.

    Google Scholar 

  21. Woods JW, Blythe WB: Management of malignant hypertension complicated by renal insufficiency. N Engl J Med 277:57–61, 1967.

    Article  PubMed  CAS  Google Scholar 

  22. Woods JW, Blythe WB, Huffines WD: Management of malignant hypertension complicated by renal insufficiency. N Engl J Med 291:10–14, 1974.

    Article  PubMed  CAS  Google Scholar 

  23. Okuda S, Onoyama K, Fujimi S, Oh Y, Nomoto K, Omae T: Influence of hypertension on the progression of experimental autologous immune complex nephritis. J Lab Clin Med 101:461–470, 1983.

    CAS  Google Scholar 

  24. Brenner BM: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23:647–655, 1983.

    Article  PubMed  CAS  Google Scholar 

  25. Freis ED: Does moderate sodium restriction lower blood pressure? Hypertension 8:265–266, 1986.

    PubMed  CAS  Google Scholar 

  26. Ram CVS, Garrett BN, Kaplan NM: Moderate restriction and various diuretics in the treatment of hypertension. Effects on potassium wastage and blood pressure control. Arch Intern Med 141:1015–1919, 1981.

    Article  PubMed  CAS  Google Scholar 

  27. Kaplan NM: Management strategies in hypertension. Con-temp Issues Nephrol 4:339–366, 1981.

    Google Scholar 

  28. Suki WN, Dawoud F, Eknoyan G, Martinez MM: Effects of metolazone on renal function in normal man. J Pharm Exp Ther 180:6–12, 1972.

    CAS  Google Scholar 

  29. Frishman WH: ß-adrenoreceptor antagonists: New drus and new indications. N Engl J Med 305:500–506, 1981.

    Article  PubMed  CAS  Google Scholar 

  30. The Norwegian Multi-Center Study Group. Timolol-induced reduction in morality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801–807, 1981.

    Article  Google Scholar 

  31. Braunwald E, Muller JE, Kloner RA, Maroko PR: Role of beta-adrenergic blockade in the therapy of patients with myocardial infarction. Am J Med 74:113–123, 1983.

    Article  PubMed  CAS  Google Scholar 

  32. Weber MA, Drayer JIM: Renal effects of beta-adrenoreceptor-blockade. Kidney Int 18:686–699, 1980.

    Article  PubMed  CAS  Google Scholar 

  33. Wright AD, Barber SG, Kendall MJ: Beta-adrenoreceptor blocking drugs and blood sugar control in diabetes mellitus. Br Med J 1:159–161, 1979.

    Article  PubMed  CAS  Google Scholar 

  34. Greenblatt DJ, Koch-Wesser J: Adverse reactions to propranolol in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J 86:478–485, 1973.

    Article  PubMed  CAS  Google Scholar 

  35. Rosa RM, Silva P, Young JB, Brown RS, Rowe JW, Epstein FH: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 302:431–434, 1980.

    Article  PubMed  CAS  Google Scholar 

  36. Frohlich ED: Methyldopa. Mechanism and treatment 25 years later. Arch Intern Med 140:954–959, 1981.

    Article  Google Scholar 

  37. Pettinger WA: Clonidine, a new antihypertensive drug. N Engl J Med 293:1179–1180, 1975.

    Article  PubMed  CAS  Google Scholar 

  38. Saameli K, Jerie P, Scholtysik G: Guanfacine and other centrally acting drugs in antihypertensive therapy: Pharmacological and clinical aspects. Clin Exp Hypertension 4:209–219, 1982.

    Article  CAS  Google Scholar 

  39. Chidsey CA, Gottlieb TB: The pharmacological basis of antihypertensive therapy: The role of vasodilator drugs. Prog Cardiovasc Dis 17:99–113, 1974.

    Article  PubMed  Google Scholar 

  40. Koch-Wesser J: Hydralazine. N Engl J Med 295:61–65, 1981.

    Google Scholar 

  41. Graham RM, Pettinger WA: Prazosin. N Engl J Med 300:232–236, 1979.

    Article  PubMed  CAS  Google Scholar 

  42. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of prazosin with hydralazine in patients receiving hydrochlorothiazide. A randomized, double-blind clinical trial. Circulation 64:772–779, 1981.

    Article  Google Scholar 

  43. Keusch GW, Weidmann P, Campese V, Lee DBN, Upham AT, Massry SG: Minoxidil therapy in refractory hypertension. Analysis of 155 patients. Nephron 21:1–15, 1979.

    Article  Google Scholar 

  44. Mitchell JC, Graham RM, Pettinger WA: Renal function during long-term treatment of hypertension with minoxidil. Comparison of benign and malignant hypertension. Ann Intern Med 93:676–681, 1980.

    PubMed  CAS  Google Scholar 

  45. Ram CVS: Clinical application of therapeutic advances. Captopril. Arch Intern Med 142:914–916, 1982.

    Article  PubMed  CAS  Google Scholar 

  46. Rubin B, Antonaccio MJ, Horowitz ZP: Captopril: A new orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent. Prog Cardiovasc Dis 21:183–187, 1978.

    Article  PubMed  CAS  Google Scholar 

  47. Vidt DG, Bravo EL, Fouad FM: Captopril. N Engl J Med 306:214–219, 1982.

    Article  PubMed  CAS  Google Scholar 

  48. Bauer JH, Reams GP, Lal SM: Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 147:1397–1400, 1987.

    Article  PubMed  CAS  Google Scholar 

  49. Zatz R, Anderson S, Meyer TW, Dunn BR, Rennke HG, Brenner BM: Lowering arterial blood pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes. Kidney Int 31 (Suppl 20):S123-S129, 1987.

    Google Scholar 

  50. Hostetter TH, Rennke HG, Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 73:375–380, 1982.

    Article  Google Scholar 

  51. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensin converting-enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 293:471–474, 1986.

    Article  CAS  Google Scholar 

  52. Levenson DJ, Dzau VJ: Effects of angiotensin-converting enzyme inhibition on renal hemodynamics in renal artery stenosis. Kidney Int 31 (Suppl 20):S173-S179, 1987.

    CAS  Google Scholar 

  53. Mujais SK, Fouad FM, Textor SC, Tarazi RC, Bravo EL, Hart N, Gifford RW: Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J 52:63–71, 1984.

    Article  PubMed  CAS  Google Scholar 

  54. Textor SC, Bravo E, Fouad FM: Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with Captopril. Am J Med 73:719–725, 1982.

    Article  PubMed  CAS  Google Scholar 

  55. Ram CVS: Calcium antagonists in the treatment of hypertension. Am J Med Sci 290:118–133, 1985.

    Article  PubMed  CAS  Google Scholar 

  56. Loutzenhiser R, Epstein M: Effects of calcium antagonists on renal hemodynamics. An editorial review. Am J Physiol 249:F616-F621, 1985.

    Google Scholar 

  57. Koch-Wesser J: Hypertensive emergencies. N Engl J Med 290:211–214, 1974.

    Article  Google Scholar 

  58. Keith TA: Hypertension crisis. Recognition and management. J A M A 237:1570–1577, 1977.

    Article  PubMed  Google Scholar 

  59. Carry CL: Current treatment of malignant hypertension. J A M A 232:1367–1369, 1975.

    Article  Google Scholar 

  60. Ram CVS: Hypertensive encephalopathy — recognition and management. Arch Intern Med 138:1851–1853, 1978.

    Article  PubMed  CAS  Google Scholar 

  61. Bhatia SK, Frohlich ED: Hemodynamic comparison of agents useful in hypertensive emergencies. Am Heart J 85:367–373, 1973.

    Article  Google Scholar 

  62. Cohn JH, Burke LP: Nitroprusside. Ann Intern Med 91:752–757, 1979.

    PubMed  CAS  Google Scholar 

  63. Ram CVS, Kaplan NM: Individual titration of diazoxide dosage in the treatment of severe hypertension. Am J Cardiol 43:627–630, 1979.

    Article  PubMed  CAS  Google Scholar 

  64. Houston MC: Treatment of hypertensive emergencies and urgencies with oral Clonidine loading and titration. A review. Arch Intern Med 146:586–589, 1986.

    Article  PubMed  CAS  Google Scholar 

  65. Haft JI, Litterer WE: Chewing nifedipine to rapidly treat hypertension. Arch Intern Med 144:2357–2359, 1984.

    Article  PubMed  CAS  Google Scholar 

  66. Wilson DJ, Wallin JD, Vlachakis ND, Freis ED, Vidt DG, Michelson EL, Langford HG, Flamenbaum W, Poland MP: Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med 74:95–102, 1983.

    Article  Google Scholar 

  67. Brollaz J, Waeber B, Brunner HR: Hypertensive crisis treated with orally administered Captopril. Eur J Clin Pharmacol 25:145–149, 1983.

    Article  Google Scholar 

  68. Reams GP, Lal SM, Whalen JJ, Bauer JH: Enalaprilat — an intravenous substitute for oral enalapril therapy. J Clin Hypertension 3:245–253, 1986.

    Google Scholar 

  69. Byrom FB: The evolution of acute hypertensive arterial disease. Prog Cardiovasc Dis 17:31–37, 1974.

    Article  PubMed  CAS  Google Scholar 

  70. MacMahon HE: Malignant nephrosclerosis — A reappraisal. Pathol Ann 3:297–334, 1968.

    Google Scholar 

  71. Allison PR, Bleeham N, Brown W, Pickering GW, Robb-Smith AHT, Russell RP: The production and resolution of hypertensive vascular lesions in the rabbit. Clin Sci 33:39–51, 1967.

    PubMed  CAS  Google Scholar 

  72. Pickering G: Reversibility of malignant hypertension. Follow-up of three cases. Lancet 1:413–418, 1971.

    Article  PubMed  CAS  Google Scholar 

  73. Mroczek WJ, Davidov M, Gavrilovich L, Finnerty F: The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 40:893–904, 1969.

    Google Scholar 

  74. Friedlander MM, Rubinger D, Popovtzer MM: Improved renal function in patients with primary renal disease after control of severe hypertension. Am J Nephrol 2:12–14, 1982.

    Article  Google Scholar 

  75. Eknoyan G, Siegel MB: Survival from anuria due to malignant hypertension. J A M A 215:1122–1125, 1971.

    Article  PubMed  CAS  Google Scholar 

  76. Dichoso CC, Minuth ANW, Eknoyan G: Malignant hypertension: Recovery of kidney function after renal allograft failure. Arch Intern Med 135:300–303, 1975.

    Article  PubMed  CAS  Google Scholar 

  77. Ram CVS, Hyman D: Hypertensive crisis. J Intensive Care Med 2:151–162, 1987.

    Article  Google Scholar 

  78. Mahoney JF, Gibson GR, Shiel AGR, Storey BG, Stokes GS, Stewart JH: Bilateral nephrectomy for malignant hypertension. Lancet 1:1036–1038, 1972.

    Article  Google Scholar 

  79. McCarron DA, Rubin RJ, Varnes BA, Harrington JT, Nillan EG: Therapeutic bilateral renal infarction in end-stage renal disease. N Engl J Med 294:652, 1976.

    Article  PubMed  CAS  Google Scholar 

  80. Pettinger WA, Mitchell JC: Minoxidil. An alternative to nephrectomy for refractory hypertension. N Engl J Med 289:167–171, 1973.

    Article  PubMed  CAS  Google Scholar 

  81. Mroczek WJ: Malignant hypertension: Kidneys too good to be extirpated. Ann Intern Med 80:754–757, 1974.

    PubMed  CAS  Google Scholar 

  82. Maxwell MH, Bleifer KH, Franklin SJ, Varady PO: Demographic analysis of the study. J A M A 220:1195–1204, 1972.

    Article  PubMed  CAS  Google Scholar 

  83. Simon N, Franklin SS, Bleifer KH, Maxwell MH: Characteristics of renovascular hypertension. J A M A 220:1209–1218, 1972.

    Article  PubMed  CAS  Google Scholar 

  84. Hunt JC, Sheps SG, Harrison EG, Strong CG, Bernatz PE: Renal and renovascular hypertension. A reasoned approach to diagnosis and management. Arch Intern Med 133:988–999, 1974.

    Article  PubMed  CAS  Google Scholar 

  85. Working Group on Renovascular Hypertension: Detection, evaluation, and treatment of renovascular hypertension. Final report. Arch Intern Med 147:820–829, 1987.

    Article  Google Scholar 

  86. Jacobson HR: Ischemic renal disease: An overlooked clinical entity? Kidney Int 34:729–743, 1988.

    Article  PubMed  CAS  Google Scholar 

  87. Grim CE, Weinberger MH: Renal artery stenosis and hypertension. Semin Nephrol 3:52–64, 1983.

    Google Scholar 

  88. Dzau VJ, Gibbons GH, Levin DC: Renovascular hypertension: An update on pathophysiology, diagnosis and treatment. Am J Nephrol 3:172–184, 1983.

    Article  PubMed  CAS  Google Scholar 

  89. Brookstein JJ, Abrams HL, Buenger RE, Lecky J, Franklin SS, Reis MD, Bleifer KH, Klatte EC, Varady PD, Maxwell MH: Urography in unilateral renovascular disease. J A M A 220:1225–1230, 1972.

    Article  Google Scholar 

  90. Grim CE, Luft FC, Weinberger MH, Grim CM: Sensitivity and specificity of screening tests for renal vascular hypertension. Ann Intern Med 91:617–622, 1979.

    PubMed  CAS  Google Scholar 

  91. McNeil BJ, Varady PD, Burrows BA, Adelstein SJ: Measures of clinical efficacy: Cost effectiveness calculation in the diagnosis and treatment of hypertensive renovascular disease. N Engl J Med 293:216–221, 1975.

    Article  PubMed  CAS  Google Scholar 

  92. Hollenberg NK, Williams GH, Adams DF, Moore T, Brown C, Boruki LJ, Leung F, Bavli S, Solomon HS, Passan D, Dluhy R: Response to saralasin and angiotensin role in essential and renal hypertension. Medicine 58:115–127, 1979.

    Article  PubMed  CAS  Google Scholar 

  93. Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN: Clinical experience with blockade of the renin-angiotensin aldosterone system by an oral converting enzyme inhibitor (SO 14225, Captopril) in hypertensive patients. Prog Cardiovasc Dis 21:195–206, 1978.

    Article  PubMed  CAS  Google Scholar 

  94. Staessen J, Wilms G, Baert A, Fagard R, Lynen P, Suy R, Amery A: Blood pressure during long-term converting-enzyme inhibition predicts the curability of renovascular hypertension by angioplasty. Am J Hypertension 1:208–214, 1988.

    CAS  Google Scholar 

  95. Navis G, de Jong PE, Donker AJM, van der Hem GK, de Zeeuw D: Moderate sodium restriction in hypertensive subjects: Renal effects of ACE-inhibition. Kidney Int 31:815–819, 1987.

    Article  PubMed  CAS  Google Scholar 

  96. Sealey JE, Buhler FR, Laragh JH, Vaughan D: The physiology of renin secretion in essential hypertension: Estimation of renin secretion rate and renal plasma flow from peripheral and renal vein renin levels. Am J Med 55:391–401, 1973.

    Article  PubMed  CAS  Google Scholar 

  97. Marks LS, Maxwell MH: Renal vein renin. Value and limitations in the prediction of operative results. Urol Clin North Am 2:311–325, 1975.

    PubMed  CAS  Google Scholar 

  98. Vaughan ED, Buehler FR, Laragh JH, Sealey JE, Baer L, Bard RH: Renovascular hypertension: Renin measurements to indicate hypersecretion and contralateral suppression, estimate renal blood flow, and score for surgical curability. Am J Med 65:402–414, 1973.

    Article  Google Scholar 

  99. Sos TA, Pickering TG, Sniderman K, Saddekin S, Case DB, Silane MF, Vaughan ED, Laragh JH: Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. N Engl J Med 309:274–279, 1983.

    Article  PubMed  CAS  Google Scholar 

  100. Madias NE: Renovascular hypertension. Nephrology Lett 3:27–42, 1986.

    Google Scholar 

  101. Martin LG, Price RB, Casarekka WJ, Stones PJ, Wells SO, Zellmer RA, Chuang VP, Silbiger ML, Berkman WA: Percutaneous angioplasty in clinical management of renovascular hypertension: Initial and long-term results. Radiology 155:629–633, 1985.

    PubMed  CAS  Google Scholar 

  102. Krener HTK, de Jong PE, de Zeeuw D, Donker AJM, Schuur KH, van der Hem GK: Restenosis prevalence and long-term effects on renal function after percutaneous transluminal renal angioplasty. Nephron 44 (Suppl l):64–67, 1986.

    Article  Google Scholar 

  103. Geyskes GG: Treatment of renovascular hypertension with percutaneous transluminal renal angioplasty. Am J Kid Dis 12:253–265, 1988.

    PubMed  CAS  Google Scholar 

  104. Buhler FR, Laragh JH, Vaughan ED, Brunner HR, Gavras H, Baer L: The antihypertensive action of propranolol. Specific anti-renin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 32:511–522, 1973.

    Article  PubMed  CAS  Google Scholar 

  105. Case DB, Atlas SA, Marion RM, Laragh JH: Long-term efficacy of Captopril in renovascular and essential hypertension. Am J Cardiol 49:1440–1446, 1982.

    Article  PubMed  CAS  Google Scholar 

  106. Aldigier JC, Ploum P, Guyene TT, Thibonnier M, Carval P, Menard J: Comparison of the hormonal and renal effects of Captopril in severe essential and renovascular hypertension. Am J Cardiol 49:1447–1452, 1982.

    Article  PubMed  CAS  Google Scholar 

  107. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ: Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med 308:373–376, 1983.

    Article  PubMed  CAS  Google Scholar 

  108. Orabona ML, Albano O: Systemic progressive sclerosis. Acta Med Scandinav 333 (Suppl): 1–170, 1958.

    CAS  Google Scholar 

  109. Winkelmann RK: Classification and pathogenesis of scleroderma. Mayo Clin Proc 46:83–91, 1971.

    PubMed  CAS  Google Scholar 

  110. Eknoyan G, Suki WN: Renal vascular phenomena in systemic sclerosis. Semin Nephrol 5:34–45, 1985.

    PubMed  CAS  Google Scholar 

  111. Norton WL, Nardo JM: Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 73:317–324, 1970.

    PubMed  CAS  Google Scholar 

  112. Medsger TA, Masi AT, Rodnan GP, Benedek TG, Robinson H: Survival with systemic sclerosis (scleroderma): A life-table analysis of demographic and clinical factors in 309 patients. Ann Intern Med 75:369–376, 1971.

    PubMed  Google Scholar 

  113. Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy C: The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 53:1–46, 1974.

    Article  PubMed  CAS  Google Scholar 

  114. Hannigan CA, Hannigan MH, Scoh EL: Scleroderma of the kidneys. Am J Med 20:793–797, 1956.

    Article  PubMed  CAS  Google Scholar 

  115. Rodnan GP, Schreiner GE, Black RL: Renal involvement in progressive systemic sclerosis (generalized scleroderma). Am J Med 23:445–462, 1957.

    Article  PubMed  CAS  Google Scholar 

  116. Fisher ER, Rodnan GP: Pathologic observations concerning the kidney in progressive systemic sclerosis. Arch Pathol 65:29–39, 1958.

    CAS  Google Scholar 

  117. Medsger TA, Masi AT: Survival with scleroderma-II: A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chron Dis 26:647–660, 1973.

    Article  PubMed  Google Scholar 

  118. Richardson JA: Hemodialysis and kidney transplantation for renal failure from scleroderma. Arthritis Rheum 16:265–271, 1973.

    Article  PubMed  CAS  Google Scholar 

  119. Shapiro CB, Lerner NE, Achad AS, Abramson R, Stein RM: Malignant hypertension and uremia in scleroderma: Efficacy of nephrectomy and hemodialysis. Clin Nephrol 8:321–323, 1977.

    PubMed  CAS  Google Scholar 

  120. Dichoso CC: The kidney in progressive systemic sclerosis (scleroderma). In: WN Suki, G Eknoyan, eds, The Kidney in Systemic Disease, 2nd ed. John Wiley & Sons, New York, pp 109–128, 1981.

    Google Scholar 

  121. Brown ST, Ahearn DJ, Nolph KD: Reduced peritoneal clearance in scleroderma increased by intraperitoneal isoproterenol. Ann Intern Med 78:891–894, 1973.

    PubMed  CAS  Google Scholar 

  122. Oliver JA, Cannon PJ: The kidney is scleroderma. Nephron 18:141–150, 1977.

    Article  PubMed  CAS  Google Scholar 

  123. LeRoy EC, Fleischmann RM: The management of renal scleroderma: Experience with dialysis, nephrectomy and transplantation. Am J Med 64:974–978, 1978.

    Article  PubMed  CAS  Google Scholar 

  124. Keane WF, Danielson B, Raij L: Successful renal transplantation in progressive systemic sclerosis. Ann Intern Med 85:199–202, 1976.

    PubMed  CAS  Google Scholar 

  125. Stone RA, Tisher CC, Hawkins HK, Robinson RR: Juxtaglomerular hyperplasia and hyperreninemia in progressive systemic sclerosis complicated by acute renal failure. Am J Med 56:119–123, 1974.

    Article  PubMed  CAS  Google Scholar 

  126. Kovalchik MT, Guggenheim SJ, Silverman MH, Robertson JS, Steigerwald JC: The kidney in porgressive systemic sclerosis: A prospective study. Ann Intern Med 89:881–887, 1978.

    PubMed  CAS  Google Scholar 

  127. Gavras H, Gavras I, Cannon PH, Brunner HR, Laragh JH: Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? Arch Intern Med 137:1554–1558, 1977.

    Article  PubMed  CAS  Google Scholar 

  128. Moorthy AV, Wu MJ, Bierne GJ, Sundstron WS: Control of hypertension and acute renal failure in scleroderma without nephrectomy. Lancet 1:563–564, 1978.

    PubMed  CAS  Google Scholar 

  129. Mitnich PD, Fieg PU: Control of hypertension and reversal renal failure in scleroderma. N Engl J Med 299:871–872, 1978.

    Article  Google Scholar 

  130. Wasner C, Cooke CR, Fries JF: Successful medical treatment of scleroderma renal crisis. N Engl J Med 299:873–875, 1978.

    Article  PubMed  CAS  Google Scholar 

  131. Lopez-Overjero JA, Saal SD, D’Angelo WA, Cheigh JS, Stenzel KH, Laragh JH: Reversal of vascular and renal crisis of scleroderma by oral angiotensin-converting enzyme blockade. N Engl J Med 300:1417–1419, 1979.

    Article  Google Scholar 

  132. Whitman HH, Case DB, Laragh JH, Christian CL, Botstein G, Maricq H, LeRoy EC: Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum 25:241–248, 1982.

    Article  PubMed  Google Scholar 

  133. Waldo R: Prazosin relieves Raynaud’s vasospasm. J A M A 241:1037, 1979.

    Article  PubMed  CAS  Google Scholar 

  134. Winkelmann RK, Kierland RR, Perry HO, Muller SA, Sams WM: Management of scleroderma. Mayo Clin Proc 46:128–134, 1971.

    PubMed  CAS  Google Scholar 

  135. Rodnan GP: Progressive systemic sclerosis (scleroderma). In: Samler, ed, Immunological Diseases, Vol. II. Little, Brown, Boston, pp 1109–1141, 1978.

    Google Scholar 

  136. Dau PC, Kahleh MB, Sagebiel RW: Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum 24:1128–1136, 1981.

    Article  PubMed  CAS  Google Scholar 

  137. Hoxie HJ, Coggin CB: Renal infarction: Statistical study of 205 cases and detailed report of an unusual case. Arch Intern Med 65:587–594, 1940.

    Google Scholar 

  138. Peterson NE, McDonald DF: Renal embolization. J Urol 100:140–145, 1968.

    PubMed  CAS  Google Scholar 

  139. Foley WJ, Kraft RO: Renal artery embolectomy. Arch Surg 103:748–751, 1971.

    PubMed  CAS  Google Scholar 

  140. Gill TJ, Dammin GJ: Paradoxical embolism with renal failure casued by occlusion of the renal arteries. Am J Med 25:780–787, 1958.

    Article  PubMed  Google Scholar 

  141. Case Record of the Massachusetts General Hospital (Case 32–1962). N Engl J Med 266:1054–1062, 1962.

    Google Scholar 

  142. Shabanah FH, Conolly JE, Martin DC: Acute renal artery occulusion. Surg Gyn Obst 131:489–494, 1970.

    PubMed  CAS  Google Scholar 

  143. Besarab A, Brown RS, Rubin NT, Salzman E, Wirthlin L, Steinman T, Atlia RR, Skillman JJ: Reversible renal failure following bilateral renal artery occlusive disease. Clinical features, pathology, and the role of surgical revascularization. J A M A 235:2838–2841, 1976.

    Article  PubMed  CAS  Google Scholar 

  144. Arakawa K, Torii S, Kibuchi Y, Nakamura M: Delayed renin release in renal infarction. Arch Intern Med 129:958–962, 1972.

    Article  PubMed  CAS  Google Scholar 

  145. Arakawa K, Torri S, Naito S, Minohara A, Vemura N, Nakamura M: Plasma renin activity as a more specific diagnostic aid for renal infarction. Arch Intern Med 125:830–834, 1970.

    Article  PubMed  CAS  Google Scholar 

  146. London IL, Hoffsten P, Perkoff GT, Pennington TG: Renal infarction. Elevation of serum and urinary lactic dehydrogenase (LDH). Arch Intern Med 121:87–90, 1968.

    Article  PubMed  CAS  Google Scholar 

  147. Duncan DA, Dexter RN: Anuria secondary to bilateral renal-artery embolism. N Engl J Med 266:971–973, 1962.

    Article  PubMed  CAS  Google Scholar 

  148. Smith SP, Hamburger RJ, Donohue JP, Grim CE: Occlusion of the artery to a solitary kidney. Restoration of renal function after prolonged anuria. J A M A 230:1306–1307, 1974.

    Article  PubMed  Google Scholar 

  149. Kerr WK, Kyle VN, Kerestici AG, Smythe CA: Renal hypothermia. J Urol 84:236–242, 1960.

    PubMed  CAS  Google Scholar 

  150. Brest AN, Bower R, Heider C: Renal functional recovery following anuria secondary to renal artery embolism. J A M A 187:540–542, 1964.

    PubMed  CAS  Google Scholar 

  151. Perkins RP, Jacobsen DS, Feder FP, Lipchik EO, Fine PH: Return of renal function after late embolectomy. N Engl J Med 276:1194–1195, 1967.

    Article  PubMed  CAS  Google Scholar 

  152. Millan VG, Sher MH, Deterling RA, Packard A, Morton JR, Harrington JT: Transcatheter thromboembolectomy of acute renal artery occlusion. Arch Surg 113:1086–1092, 1978.

    PubMed  CAS  Google Scholar 

  153. Fischer CP, Konnach JW, Cho KJ, Eckhauser FE, Stanley JC: Renal artery embolism: Therapy with intra-arterial streptokinase infusion. J Urol 125:402–404, 1981.

    PubMed  CAS  Google Scholar 

  154. Lessman RK, Johnson SF, Coburn JW, Kaufman JJ: Renal artery embolism. Clinical features and long-term follow-up of 17 cases. Ann Intern Med 89:477–482, 1978.

    PubMed  CAS  Google Scholar 

  155. Parker JM, Lord JO: Renal artery embolism. A case report with return of complete function of the involved kidney following anticoagulant therapy. J Urol 106: 339–341, 1971.

    PubMed  CAS  Google Scholar 

  156. Moyer JD, Rao CN, Widrich WC, Olsson CA: Conservative management of renal artery embolus. J Urol 109:138–143, 1973.

    PubMed  CAS  Google Scholar 

  157. Flory CM: Arterial occlusions produced by emboli from eroded aortic atheromatous plaques. Am J Path 21:549–565, 1945.

    PubMed  CAS  Google Scholar 

  158. Retan JW, Miller RE: Microembolic complications of atherosclerosis. Literature review and report of a patient. Arch Intern Med 118:534–545, 1966.

    Article  PubMed  CAS  Google Scholar 

  159. Kassirer JP: Atheroembolic renal disease. N Engl J Med 280:812–818, 1969.

    Article  PubMed  CAS  Google Scholar 

  160. Smith MC, Ghose M, Henry AR: Clinical spectrum of renal cholesterol embolization. Am J Med 71:174–180, 1981.

    Article  PubMed  CAS  Google Scholar 

  161. Jones DB, Iannaccone PM: Atheromatous emboli in renal biopsies. An ultrastructural study. Am J Path 78:261–270, 1975.

    PubMed  CAS  Google Scholar 

  162. Thurbleck WM, Castleman B: Atheromatous emboli to the kidneys after aortic surgery. N Engl J Med 257:442–477, 1957.

    Article  Google Scholar 

  163. Harrington JT, Sommers SC, Kassirer JP: Atheromatous emboli with progressive renal failure. Renal arteriography as the probably inciting factor. Ann Intern Med 68:152–160, 1968.

    PubMed  CAS  Google Scholar 

  164. Hyman BT, Landas SK, Ashman RF, Schleper RL, Robinson RA: Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 82:1233–1237, 1987.

    Article  PubMed  CAS  Google Scholar 

  165. Bruns FJ, Segel DP, Adler S: Control of cholesterol embolization by discontinuation of anticoagulant therapy. Am J Med Sci 275:105–108, 1978.

    Article  PubMed  CAS  Google Scholar 

  166. Handler FP: Clinical and pathologic significance of atheromatous embolization with episodes on the etiology of renal hypertension. Am J Med 20:366–373, 1956.

    Article  PubMed  CAS  Google Scholar 

  167. Richardson JH, Alderfer HH, Reid JD: Response of eye and brain to microemboli. Ann Intern Med 57:1013–1017, 1962.

    PubMed  CAS  Google Scholar 

  168. Case Records of Massachusetts General Hospital (Case 25–1967). N Engl J Med 276:1368–1377, 1967.

    Google Scholar 

  169. Richards AM, Eliot RS, Kanjub VI, Bloemendaal RD, Edwards JE: Cholesterol embolism. A multisystem disease masquerading as polyarteritis nodosa. Am J Cardiol 15: 696–707, 1965.

    Article  PubMed  CAS  Google Scholar 

  170. Kasinath BS: Eosinophilia as a clue to the diagnosis to the diagnosis of atheroemboli renal disease. Arch Intern Med 147:1384–1385, 1987.

    Article  PubMed  CAS  Google Scholar 

  171. Cosio F, Zager R, Sharma H: Atheroembolic renal disease causes hypocomplementemia. Lancet 2:118–121, 1985.

    Article  PubMed  CAS  Google Scholar 

  172. Anderson WR, Richards AM, Evaluation of lower extremity muscle biopsies in the diagnosis of atheroembolism. Arch Path 86:535–541, 1968.

    PubMed  CAS  Google Scholar 

  173. Baum NH, Moriel E, Carlton CE: Renal vein thrombosis. J Urol 119:443–448, 1978.

    PubMed  CAS  Google Scholar 

  174. Harrison CV, Milne MD, Steiner RE: Clinical aspects of renal vein thrombosis. Q J Med 25:285–298, 1956.

    PubMed  CAS  Google Scholar 

  175. McCarthy LJ, Titus JL, Daugherty GW: Bilateral renal vein thrombosis and the nephrotic syndrome in adults. Ann Intern Med 58:837–857, 1963.

    PubMed  CAS  Google Scholar 

  176. Baird WL, Buchanan DP: The nephrotic syndrome following thrombosis of the inferior vena cava. Am J Med 32:128–130, 1962.

    Article  PubMed  Google Scholar 

  177. Llach F, Arieff AI, Massry SG: Renal vein thrombosis and nephrotic syndrome. A prospective study of 36 adult patients. Ann Intern Med 83:8–14, 1975.

    PubMed  CAS  Google Scholar 

  178. Llach F, Papper S, Massry S: The clinical spectrum of renal vein thrombosis: Acute and chronic. Am J Med 69:819–827, 1980.

    Article  PubMed  CAS  Google Scholar 

  179. Harrington JT, Kassirer JP: Renal vein thrombosis. Ann Rev Med 33:255–262, 1982.

    Article  PubMed  CAS  Google Scholar 

  180. Llach F: Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 28:429–439, 1985.

    Article  PubMed  CAS  Google Scholar 

  181. Trew PA, Biava CG, Jacobs RP, Hopper J: Renal vein thrombosis in membranous glomerulonephropathy. Incidence and association. Medicine 57:69–82, 1978.

    Article  PubMed  CAS  Google Scholar 

  182. Rosenmann E, Pollak VE, Pirani CL: Renal vein thrombosis in the adult — a clinical and pathologic study based on renal biopsies. Medicine 47:269–335, 1968.

    Article  PubMed  CAS  Google Scholar 

  183. McFarland JB: Renal venous thrombosis in children. Q J Med 34:269–290, 1965.

    PubMed  CAS  Google Scholar 

  184. Arneil GC, MacDonald AM, Murphy AV, Sweet EM: Renal venous thrombosis. Clin Nephrol 1:119–131, 1973.

    PubMed  CAS  Google Scholar 

  185. Wegner GP, Crummy AB, Flaherty TT, Hipona FA: Renal vein thrombosis. A roentgenographic diagnosis. J A M A 209:1661–1667, 1969.

    Article  PubMed  CAS  Google Scholar 

  186. Kirulata HG, Bruce AW, Jarzylo SV, Morrin PAF: The protean manifestations of renal vein thrombosis in the adult. J Urol 115:634–638, 1976.

    Google Scholar 

  187. Kanfer A, Kleinknecht D, Broyer M, Josso F: Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh 24:562–571, 1970.

    PubMed  CAS  Google Scholar 

  188. Kendall AG, Lohmann RC, Dossetor JB: Nephrotic syndrome: A hypercoagulable state. Arch Intern Med 127:1021–1027, 1971.

    Article  PubMed  CAS  Google Scholar 

  189. Thomson C, Forbes CD, Prentice CRM, Kennedy AC: Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med 43:399–407, 1974.

    PubMed  CAS  Google Scholar 

  190. Hipona FA, Crummy AB: The roentgen diagnosis of renal vein thrombosis; clinical aspects. Am J Roentgen Rad Ther Nucl Med 93:122–131, 1966.

    Google Scholar 

  191. Mulhern CB, Arger PH, Miller WT, Chait A: The specificity of renal vein thrombosis. Am J Roentgen Rad Ther Nucl Med 125:291–299, 1975.

    CAS  Google Scholar 

  192. Rosenfield AT, Zeman RK, Cronan JJ, Taylor KJW: Ultrasound in experimental and clinical renal vein thrombosis. Radiology 137:735–741, 1980.

    PubMed  CAS  Google Scholar 

  193. Zerhouni EA, Barth KH, Ziegelman SS: Demonstration of venous thrombosis by computer tomography. Am J Roentgen Rad Ther Nucl Med 134:753–758, 1980.

    CAS  Google Scholar 

  194. Frantantoni JD, Ness P, Simon TL: Thrombolytic therapy. Current status. N Engl J Med 293:1073–1076, 1975.

    Article  Google Scholar 

  195. Hobbs DC, Twomey TM: Kinetics of polythiazide. Clin Pharmacol Ther 23:241–246, 1978.

    PubMed  CAS  Google Scholar 

  196. Beerman B, Groschinsky-Grind M: Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 12:297–303, 1977.

    Article  Google Scholar 

  197. Dargie HJ, Allison ME, Kennedy AC, Gray AJ: High dose metolazone in chronic renal failure. Br Med J 1:196–198, 1972.

    Article  Google Scholar 

  198. Tilsone WJ, Dargie JH, Dargie EN, Morgan HG, Kennedy AC: Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther 16:322–329, 1974.

    Google Scholar 

  199. Beerman B, Dalen E, Lindstron B: Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 22:70–78, 1977.

    Google Scholar 

  200. Rane A, Villeneuve JP, Stone WJ, Wilkenson JR, Branch RA: Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 24:199–207, 1978.

    PubMed  CAS  Google Scholar 

  201. Schwartz FD, Pillay V, Kark RM: Ethacrynic acid: Its usefulness and untoward effects. Am Heart J 79:427–428, 1970.

    Article  PubMed  CAS  Google Scholar 

  202. Davies DL, Lant AF, Millard NR, Smith AJ, Ward JW, Wilson GM: Renal action, therapeutic use and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther 15:141–155, 1974.

    PubMed  CAS  Google Scholar 

  203. Barclay JE, Lea HA: Clinical and pharmacokinetic studies of bumetanide in chronic renal failure. Postgrad Med J 51 (Suppl):3–46, 1975.

    Google Scholar 

  204. Karin A: Spironolactone: Disposition, metabolism, pharmacodynamics and bioavailability. Drug Metab Rev 8:151–188, 1978.

    Article  Google Scholar 

  205. Knaut H, Schnippenkotter I, Wais U, Geissler H, Grebian B, Mutschier E: Diuretic activity and renal elimination of triamterene and metabolites in renal insufficiency. Kidney Int 13:528–529, 1978.

    Google Scholar 

  206. Schwartz A, Seller R, Onesti G, Kim, Swartz C, Brest AN: Pharmacodynamic effects of a new potassium-sparing diuretic, amiloride. J Clin Pharmacol 9:217–223, 1969.

    Article  CAS  Google Scholar 

  207. Stenbock O, Myhre E, Rugstad HE, Arnold E, Hanson T: Pharmacokinetics of methyldopa in healthy man. Eur J Clin Pharmacol 12:117–123, 1977.

    Article  Google Scholar 

  208. Myhre E, Brodwall EK, Stenbock O, Hanson T: Plasma turnover of methyldopa in advanced renal failure. Acta Med Scand 191:343–347, 1972.

    PubMed  CAS  Google Scholar 

  209. Yeh BK, Dayton PG, Waters WC: Removal of alpha methyldopa (Aldomet) in man by dialysis. Proc Soc Exp Biol Med 135:840–843, 1970.

    PubMed  CAS  Google Scholar 

  210. Dollery CT, David DS, Draffon GH, Dargie JH, Dean CR, Reid JL, Clare RA, Murray S: Clinical pharmacology and pharmacokinetics of Clonidine. Clin Pharmacol Ther 19:11–17, 1976.

    PubMed  CAS  Google Scholar 

  211. Hulter HN, Licht JH, Ienicki LP, Singh S: Clinical efficacy and pharmacokinetics of Clonidine in hemodialysis and renal insufficiency. J Lab Clin Med 93:223–231, 1979.

    Google Scholar 

  212. Stitzel RE: The biological fate of reserpine. Pharmacol Rev 28:179–208, 1976.

    PubMed  CAS  Google Scholar 

  213. Zoster TT, Johnson GE, DeVeber GA, Paul H: Excretion and metabolism of reserpine in renal failure. Clin Pharmacol Ther 14:325–330, 1973.

    Google Scholar 

  214. Baure JH: Effects of guanabenz therapy on renal function and body fluid composition. Arch Intern Med 143:1163–1167, 1983.

    Article  Google Scholar 

  215. Carchman SH, Crowe JT: Steady-state plasma levels and pharmacokinetics of guanfacine in hypertensive patients with normal renal function. Clin Pharmacol Ther 37:186–192, 1985.

    Google Scholar 

  216. Wilkinson R: B-blockers and renal function. Drugs 23:195–206, 1982.

    Article  PubMed  CAS  Google Scholar 

  217. Johnsson G, Regardh CG: Clinical pharmacokinetics of B-adrenoreceptor blocking drugs. Clin Pharmacokinet 1:233–263, 1976.

    Article  PubMed  CAS  Google Scholar 

  218. Reidenberg MM, Drayer D, De Marco AL, Bello CT, Hydralazine elimination in man. Clin Pharmacol Ther 14:970–977, 1973.

    PubMed  CAS  Google Scholar 

  219. Talseth T: Studies on hydralazine: Elimination and steady-state concentration in patients with impaired renal function. Eur J Clin Pharmacol 10:311–317, 1976.

    Article  PubMed  CAS  Google Scholar 

  220. Gottlieb TB, Thomas RC, Chedsey CA: Pharmacokinetic studies of minoxidil. Clin Pharmacol Ther 13:436–441, 1972.

    PubMed  CAS  Google Scholar 

  221. Lowenthal DT, Mutterperl RE, Zinns G: Bioavailability, pharmacokinetics and pharmacodynamics of minoxidil in chronic renal failure (abstract). Clin Pharmacol Ther 21:109, 1977.

    Google Scholar 

  222. Rommel AJ, Pieridew AM, Heald A: Captopril elimination in chronic renal failure. Clin Pharmacol Ther 27:282, 1980.

    Google Scholar 

  223. Todd PA, Heel RC: Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31:198–248, 1986.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Garabed Eknoyan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, The Methodist Hospital, Houston, Texas, USA

    Wadi N. Suki

  2. Division of Nephrology, University of Southern California, Los Angeles, California, USA

    Shaul G. Massry

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Kluwer Academic Publishers

About this chapter

Cite this chapter

Eknoyan, G. (1991). Noninflammatory Vascular Diseases of the Kidney. In: Suki, W.N., Massry, S.G. (eds) Therapy of Renal Diseases and Related Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0689-4_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-0689-4_28

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8027-9

  • Online ISBN: 978-1-4613-0689-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation